ATL. Issue 8 (1st October 2014)

• Record Type: Journal Article
• Authors: Rudaitis, Vilius; Zvirblis, Tadas; Kanopiene, Daiva; Janulynaite, Dovile; Griskevicius, Laimonas; Janavicius, Ramunas
• Is Part Of: International journal of gynecological cancer. Volume 24:Issue 8(2014)
• Page Start: 1395
• Page End: 1400
• Publication Date: 2014-10-01
• Subjects: BRCA1 -- BRCA2 -- Cytoreductive surgery -- Founder mutation; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1097/IGC.0000000000000247
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objective: The aim of this study was to explore BRCA mutation frequency and to evaluate its impact on prognosis of advanced-stage ovarian cancer patients treated with debulking surgery and platinum-based chemotherapy. Methods: Patients with advanced-stage epithelial ovarian cancer were enrolled in a prospective, single-center study from September 2008 to December 2011. All cases were screened for BRCA1 and BRCA2 gene mutations. Progression-free survival (PFS) was assessed between BRCA1/2 mutation carriers and BRCA1/2 wild-type patients. Results: One hundred seven patients were enrolled and screened for BRCA1 and BRCA2 mutations; 51.4% patients were positive for BRCA1/2 gene mutation, 63.6% of which carried a single Baltic mutation, and 98.2% of them had serous histology. Older age (hazard ratio [HR], 1.032; 95% confidence interval [CI], 1.010–1.055; P = 0.0047), nonoptimal cytoreduction (HR, 3.170; 95% CI, 1.986–5.060; P < 0.0001), and BRCA1/2 wild type (HR, 1.625 [1.003–2.632]; P = 0.0486) were significantly associated with shorter PFS in multivariate Cox regression analysis. Only the nonoptimal cytoreduction was a statistically significant risk factor for shorter overall survival (HR, 2.684; 95% CI, 1.264–5.701; P = 0.0102). Conclusions: Advanced ovarian cancer patients harboring BRCA1/2 mutation treated with debulking surgery and platinum-based adjuvant chemotherapy have a longer PFS.